Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2, Randomized, Open Label, Multicenter Study of Intradermal IMA901 Plus GM-CSF With or Without Low Dose Cyclophosphamide Pre-treatment in Advanced Renal Cell Carcinoma Patients With Measurable Disease

NCT00523159 is registered in ClinicalTrials.gov with Immatics Biotechnologies GmbH as lead sponsor.

NCT NCT00523159
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00523159 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2, Randomized, Open Label, Multicenter Study of Intradermal IMA901 Plus GM-CSF With or Without Low Dose Cyclophosphamide Pre-treatment in Advanced Renal Cell Carcinoma Patients With Measurable Disease
Lead sponsor
Immatics Biotechnologies GmbH
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2007
Completion date
August 31, 2009
Enrollment
68 (actual)
Sites
44

Conditions

As the registry lists them; a condition with its own page is linked.

renal cell carcinoma